BIODEXA PHARMA ADR O.N. Aktie Logo
US59564R8079

BIODEXA PHARMA ADR O.N. Aktie

Ins Portfolio
Über 2000 Dividenden-Werte in einem kostengünstigen ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Für dieses Unternehmen liegen uns keine Analysten-Daten vor.

Scoring-Modelle

Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.

News

  • Foto von Notice of General Meeting

    Notice of General Meeting

    April 17, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 2 May 2025 at 13:00 BST was posted to shareholders yesterday. The Board of Directors is proposing three resolutions: Ordinary Resolutions1.» Mehr auf globenewswire.com

  • Foto von Preliminary Results for the Year Ended 31 December 2024

    Preliminary Results for the Year Ended 31 December 2024

    April 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces its audited preliminary results for the year ended 31 December 2024. For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO Tel: +44 (0)29 2048 0180 www.biodexapharma.com About Biodexa Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs.» Mehr auf globenewswire.com

  • Foto von With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

    With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

    CARDIFF, UNITED KINGDOM / ACCESS Newswire / March 19, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is making progress in readying the launch of a phase 3 trial for eRapa, its proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP).» Mehr auf accessnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte BIODEXA PHARMA ADR O.N. Aktie einen Umsatz von 0,00 und ein Nettoeinkommen von 3,90 Mio
(EUR)Juni 2024
YOY
Umsatz0,00-
Bruttoeinkommen2,58 Mio-
Nettoeinkommen3,90 Mio-
EBITDA4,90 Mio-

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+2,05k
Anzahl Aktien
1,67k
52 Wochen-Hoch/Tief
+64,90 - +1,00
DividendenNein
Beta
1,71
KGV (PE Ratio)
0,00
KGWV (PEG Ratio)
0,00
KBV (PB Ratio)
0,00
KUV (PS Ratio)
+0,02

Unternehmensprofil

Name
BIODEXA PHARMA ADR O.N. Aktie
CEO
Stephen Anthony Stamp
Mitarbeiter13
🍪

Parqet nutzt Cookies.Erfahre Mehr